Companies that manufacture, distribute, and/or market unapproved formulations of the oral, single ingredient forms of the gout drug colchicine have been ordered to stop doing so, the Food and Drug Administration announced on Sept. 30.
New data from a large Swedish cohort suggest that screening mammography in women aged 40-49 years reduced the risk of breast cancer mortality by 26%, compared with women in that age group who were not screened. The results were presented Sept. 29 during a press briefing in advance of the annual Breast Cancer Symposium sponsored by the American Society of Clinical Oncology.
The insulin-like growth factor 1 receptor may offer a much-needed therapeutic target for triple-negative breast cancer, which can be notoriously difficult to treat.
An intensive lifestyle intervention produced significant improvements in weight, cardiovascular fitness, blood pressure, hemoglobin A, triglycerides, and HDL-cholesterol, which were largely maintained throughout 4 years of follow-up, according to a report in the Sept. 27 issue of the Archives of Internal Medicine.
Although the Food and Drug Administrations decision to keep rosiglitazone on the market with a risk management program in place that preserves some access to the controversial diabetes drug, the plan is expected to squelch most prescribing and therefore, could have an effect that approaches that in Europe, where it will no longer be marketed.
For patients with severe aortic stenosis who cannot withstand surgery, transcatheter aortic valve implantation markedly reduces mortality from any cause, cardiovascular mortality, the need for hospitalization, and cardiac symptoms, according to a report from the PARTNER trial published online Sept. 22 in the New England Journal of Medicine.
Antipsychotic drugs are associated with an almost one-third (32%) greater risk of venous thromboembolism, according to results of a nested case-control study of more than 100,000 primary care patients in the United Kingdom. The study was published online Sept. 21 in the British Medical Journal.
SILVER SPRING, Md. (EGMN) A Food and Drug Administration advisory panel on Sept. 20 unanimously voted to recommend that dabigatran, an orally administered direct thrombin inhibitor, be approved for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
The U.S. Food and Drug Administration has announced that it is reviewing safety data on the diabetes drug Actos (pioglitazone).
ADELPHI, Md.A Food and Drug Administration advisory on Sept. 16 panel voted 9-5 that the potential risks of the serotoninergic drug lorcaserin outweighed its potential benefits as a long-term treatment for weight loss in overweight and obese people and, therefore, did not support approval.
